NLRP3 and myocardial infarction: In patients with a recent myocardial infarction, the use of colchicine, an anti-inflammatory drug with NLRP3 inhibition activity [96], significantly lowered the risk (compared to the placebo) of ischemic cardiovascular events, such as death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, and urgent hospitalization for angina leading to coronary revascularization [97].